[A prospective multicenter clinical study of Xuebijing injection in the treatment of XXXX and @entity881 ].

@entity1 @entity5773 @entity295 @entity8654 @entity648 @entity772 @entity24604 @entity880 @entity881 @entity1011 @entity413
OBJECTIVE: To evaluate the clinical efficacy and safety of Xuebijing injection in treatment of @entity295 and @entity881 ( @entity881 ). METHODS: A prospective multicenter clinical study was conducted. The @entity1 with @entity295 , severe @entity295 , or @entity881 admitted to Department of Emergency and Critical Care Medicine of 70 hospitals across the country during 2006 to 2008 were enrolled. All of the @entity1 received the basis treatment of conventional therapy, plus Xuebijing injection of 50-100 mL, 2-3 times a day for 5-7 days, and the dose might be increased in serious cases. The vital signs, 24-hour urine output, Glasgow @entity772 score ( GCS ), white blood cell count ( WBC ), platelet count ( PLT ), Marshall score, gastrointestinal function score, syndrome of traditional Chinese medicine ( TCM ), blood @entity880 ( @entity24604 ), blood @entity413 , serum @entity1011 ( SCr ), and total @entity648 ( TBil ) were observed before treatment, 1, 3, and 5 days after treatment, and at the end of the treatment. The results of above mentioned parameters after the treatment were compared with that before treatment in each @entity1 . At the same time, the occurrence and the degree of adverse reactions were recorded to evaluate the safety of Xuebijing injection. RESULTS: A total of 2 574 @entity1 were enrolled, and in 2 509 cases the treatment was completed in, with a drop of 65 cases. 704 cases were diagnosed to have @entity295 , 768 with severe @entity295 , and 1 037 with @entity881 . According to TCM, in 1 951 cases syndrome of stasis-toxin in the interior, and in 558 syndrome of excessive exuberance of heat-toxic in the interior were diagnosed. After the treatment of Xuebijing injection combined with conventional therapy, the temperature, heart rate, respiration rate, blood pressure, WBC, PLT, GCS, 24-hour urine output, blood @entity413 , @entity24604 , SCr, TBil, Marshall score, gastrointestinal function score, as well as the symptoms, signs and @entity5773 and pulse condition, and TCM scores were significantly improved in all @entity1 as well as the @entity1 with @entity295 , severe @entity295 , or @entity881 ( P < 0.05 or P < 0.01 ). The effective rate of all @entity1 and the @entity1 with @entity295 , severe @entity295 , or @entity881 was 89.20% ( 2 238/2 509 ), 92.76% ( 653/704 ), 91.54% ( 703/768 ), 85.05% ( 882/1 037 ), respectively, and the 28-day survival rate was 93.90% ( 2 356/2 509 ), 98.01% ( 690/704 ), 96.35% ( 740/768 ), 89.30% ( 926/1 037 ), respectively. In 3 @entity1 with @entity881 adverse events ( 0.12% ) occurred, including 2 cases of stress ulcer and 1 case of @entity8654 . After clinical evaluation, the adverse events were found to be unrelated with the study medication, and Xuebijing injection was continued till the end of treatment. CONCLUSIONS: Xuebijing injection combined with conventional therapy may effectively ameliorate systemic inflammatory response, protect organ function, alleviate the symptoms, improve organ functions, and elevate the clinical cure rate. Adverse events occur occasionally. Xuebijing injection is found to be safe.
